{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:50:32Z","timestamp":1793242232270,"version":"4.5.0"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2011,8,9]],"date-time":"2011-08-09T00:00:00Z","timestamp":1312848000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0022662","type":"journal-article","created":{"date-parts":[[2011,8,9]],"date-time":"2011-08-09T16:50:26Z","timestamp":1312908626000},"page":"e22662","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":109,"title":["A Double Blind, Placebo-Controlled, Randomized Crossover Study of the Acute Metabolic Effects of Olanzapine in Healthy Volunteers"],"prefix":"10.1371","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct00741026","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Vance L.","family":"Albaugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Singareddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mauger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,8,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.schres.2008.04.023","article-title":"Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.","volume":"103","author":"JM Meyer","year":"2008","journal-title":"Schizophr Res"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.4088\/JCP.v67n0513","article-title":"Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis.","volume":"67","author":"DC Henderson","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.62.1.19","article-title":"Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.","volume":"62","author":"DC Henderson","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4088\/JCP.v69n0320","article-title":"Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.","volume":"69","author":"R van Winkel","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.schres.2007.12.487","article-title":"Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.","volume":"101","author":"JM Meyer","year":"2008","journal-title":"Schizophr Res"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.4088\/JCP.v68n1113","article-title":"A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.","volume":"68","author":"R Perez-Iglesias","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.4088\/JCP.08m04446yel","article-title":"Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.","volume":"70","author":"RC Smith","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2009.03.025","article-title":"Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study.","volume":"111","author":"JK Patel","year":"2009","journal-title":"Schizophr Res"},{"key":"ref9","article-title":"Forbes.com website, \u201cThe Best-Selling Drugs in America.\u201d","author":"M Herper","year":"2006"},{"key":"ref10","year":"2010"},{"key":"ref11","article-title":"Center for Disease Control Website."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1192\/bjp.183.6.534","article-title":"Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study.","volume":"183","author":"RG McCreadie","year":"2003","journal-title":"Br J Psychiatry"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0269881107075509","article-title":"Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia.","volume":"21","author":"AH Barnett","year":"2007","journal-title":"J Psychopharmacol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1192\/bjp.186.6.455","article-title":"Metabolic syndrome and schizophrenia.","volume":"186","author":"JH Thakore","year":"2005","journal-title":"Br J Psychiatry"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/1359786810382149","article-title":"The paradox of premature mortality in schizophrenia: new research questions.","volume":"24","author":"HJ Wildgust","year":"2010","journal-title":"J Psychopharmacol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1210\/jc.2008-1815","article-title":"Effects of olanzapine and haloperidol on the metabolic status of healthy men.","volume":"95","author":"S Vidarsdottir","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/sj.mp.4002000","article-title":"Metabolomic mapping of atypical antipsychotic effects in schizophrenia.","volume":"12","author":"R Kaddurah-Daouk","year":"2007","journal-title":"Mol Psychiatry"},{"key":"ref18","first-page":"20","article-title":"Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.","volume":"68","author":"JW Newcomer","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.","volume":"19","author":"JW Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"ref20","article-title":"Atypical Antipsychotics Rapidly and Inappropriately Switch Peripheral Fuel Utilization to Lipids, Impairing Metabolic Flexibility in Rodents.","author":"VL Albaugh","year":"2010","journal-title":"Schizophr Bull"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/JCP.0b013e318184b4c5","article-title":"Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration.","volume":"28","author":"AF Chintoh","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.npp.1301209","article-title":"Acute Effects of Atypical Antipsychotics on Whole-Body Insulin Resistance in Rats: Implications for Adverse Metabolic Effects.","volume":"32","author":"KL Houseknecht","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.appet.2006.01.008","article-title":"Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration.","volume":"46","author":"J Minet-Ringuet","year":"2006","journal-title":"Appetite"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00213-007-0833-9","article-title":"The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats.","volume":"194","author":"MJ Fell","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/oby.2006.6","article-title":"Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents.","volume":"14","author":"VL Albaugh","year":"2006","journal-title":"Obesity"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00213-005-2224-4","article-title":"A parametric analysis of olanzapine-induced weight gain in female rats.","volume":"181","author":"GD Cooper","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/026988110201600402","article-title":"Characterization of olanzapine-induced weight gain in rats.","volume":"16","author":"AJ Goudie","year":"2002","journal-title":"J Psychopharmacol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/0269881106069637","article-title":"Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities.","volume":"21","author":"GD Cooper","year":"2007","journal-title":"J Psychopharmacol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.1210\/jc.2002-021884","article-title":"Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp.","volume":"88","author":"M Sowell","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1210\/jcem.87.6.8599","article-title":"Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.","volume":"87","author":"MO Sowell","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/mp.2010.33","article-title":"Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis.","volume":"16","author":"VL Albaugh","year":"2011","journal-title":"Mol Psychiatry"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.2337\/diab.45.8.1044","article-title":"Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production.","volume":"45","author":"G Boden","year":"1996","journal-title":"Diabetes"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/0168-8227(89)90074-0","article-title":"Circadian rhythms of insulin needs and actions.","volume":"6","author":"W Waldhausl","year":"1989","journal-title":"Diabetes Res Clin Pract"},{"key":"ref34","doi-asserted-by":"crossref","DOI":"10.1002\/0470854596","article-title":"Cross-over trials in clinical research","author":"S Senn","year":"2002"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1192\/bjp.179.1.59","article-title":"Effects of long-term treatment with antipsychotics on serum leptin levels.","volume":"179","author":"A Herran","year":"2001","journal-title":"Br J Psychiatry"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4088\/JCP.v62n1102","article-title":"Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics.","volume":"62","author":"S Hagg","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/sj.npp.1300563","article-title":"Plasma leptin and adiposity during antipsychotic treatment of schizophrenia.","volume":"30","author":"DW Haupt","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1177\/0269881109102543","article-title":"Acute effects of olanzapine on behavioural expression including the behavioural satiety sequence in female rats.","volume":"24","author":"GD Cooper","year":"2010","journal-title":"Journal of psychopharmacology"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2008.06.105","article-title":"The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: Comparison with aripiprazole, ziprasidone, bifeprunox and F15063.","volume":"592","author":"MB Assie","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"ref40","first-page":"8","article-title":"Antipsychotic medications: metabolic and cardiovascular risk.","volume":"68","author":"JW Newcomer","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"ref41","first-page":"S170","article-title":"Metabolic syndrome and mental illness.","volume":"13","author":"JW Newcomer","year":"2007","journal-title":"Am J Manag Care"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.4088\/JCP.1106e16","article-title":"Medical risk in patients with bipolar disorder and schizophrenia.","volume":"67","author":"JW Newcomer","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1176\/appi.ajp.158.10.1719","article-title":"Association of olanzapine-induced weight gain with an increase in body fat.","volume":"158","author":"U Eder","year":"2001","journal-title":"Am J Psychiatry"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s002130000639","article-title":"Insulin and leptin levels in patients with schizophrenia or related psychoses\u2013a comparison between different antipsychotic agents.","volume":"154","author":"KI Melkersson","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.npp.1301541","article-title":"Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers.","volume":"33","author":"J Sacher","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cmet.2007.10.013","article-title":"Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance.","volume":"7","author":"TR Koves","year":"2008","journal-title":"Cell Metab"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2337\/db08-0281","article-title":"Fatty acid oxidation and insulin action: when less is more.","volume":"57","author":"DM Muoio","year":"2008","journal-title":"Diabetes"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-4800(85)90015-2","article-title":"Animal models in atherosclerosis research.","volume":"42","author":"MP Jokinen","year":"1985","journal-title":"Exp Mol Pathol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/schbul\/sbn023","article-title":"Secondary Effects of Antipsychotics: Women at Greater Risk Than Men.","volume":"35","author":"MV Seeman","year":"2009","journal-title":"Schizophr Bull"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0022662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T12:35:17Z","timestamp":1540211717000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0022662"}},"subtitle":[],"editor":[{"given":"Massimo","family":"Federici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,8,9]]},"references-count":49,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2011,8,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0022662","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,9]]}}}